Inviragen
Fort Collins
About Inviragen
Inviragen is focused on developing life-saving vaccines to protect against emerging infectious diseases worldwide. Inviragen's lead product is a vaccine to protect against dengue fever, a disease that threatens 2.5 billion people across the globe. Inviragen is also developing a vaccine to protect against West Nile for the North American market, a nasal combination vaccine to protect against both plague and smallpox for biodefense, and a unique vaccine to protect against avian influenza for global markets.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $15.0M
- Funding stage: M&A
- Last round: Series A (Oct 2009)
- Website: inviragen.com
- Phone: +1 9703720693
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/inviragen-3322490 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.